Targeted intraoperative radiotherapy (targit) yields very low recurrence rates when given as a boost

• Verfasst von: Vaidya, Jayant S. [VerfasserIn]
• Verfasst von: Baum, Michael [VerfasserIn]
• Verfasst von: Tobias, Jeffrey S. [VerfasserIn]
• Verfasst von: Massarut, Samuele [VerfasserIn]
• Verfasst von: Wenz, Frederik [VerfasserIn]
• Verfasst von: Murphy, Olive [VerfasserIn]
• Verfasst von: Hilaris, Basil [VerfasserIn]
• Verfasst von: Houghton, Joan [VerfasserIn]
• Verfasst von: Saunders, Christobel [VerfasserIn]
• Verfasst von: Corica, Tammy [VerfasserIn]
• Verfasst von: Roncadin, Mario [VerfasserIn]
• Verfasst von: Kraus-Tiefenbacher, Uta [VerfasserIn]
• Verfasst von: Melchaert, Frank [VerfasserIn]
• Verfasst von: Keshtgar, Mohammed [VerfasserIn]
• Verfasst von: Sainsbury, Richard [VerfasserIn]
• Verfasst von: Douek, Michael [VerfasserIn]
• Verfasst von: Harrison, Elly [VerfasserIn]
• Verfasst von: Thompson, Alastair [VerfasserIn]
• Verfasst von: Joseph, David [VerfasserIn]
• Titel: Targeted intraoperative radiotherapy (targit) yields very low recurrence rates when given as a boost
• Verf.angabe: Jayant S. Vaidya, Michael Baum, Jeffrey S. Tobias, Samuele Massarut, Frederik Wenz, Olive Murphy, Basil Hilaris, Joan Houghton, Christobel Saunders, Tammy Corica, Mario Roncadin, Uta Kraus-Tiefenbacher, Frank Melchaert, Mohammed Keshtgar, Richard Sainsbury, Michael Douek, Elly Harrison, Alastair Thompson, David Joseph
• E-Jahr: 2006
• Jahr: 2 November 2006
• Umfang: 4 S.
• Fussnoten: Gesehen am 24.02.2022
• Titel Quelle: Enthalten in: International journal of radiation oncology, biology, physics
• Ort Quelle: Amsterdam [u.a.] : Elsevier Science, 1975
• Jahr Quelle: 2006
• Band/Heft Quelle: 66(2006), 5, Seite 1335-1338
• ISSN Quelle: 1879-355X
• DOI: doi:10.1016/j.ijrobp.2006.07.1378
• Datenträger: Online-Ressource
• Sprache: eng
• Sach-SW: boost
• Sach-SW: brachytherapy
• Sach-SW: breast cancer
• Sach-SW: breast-conserving surgery
• Sach-SW: early breast-cancer
• Sach-SW: radiation
• Sach-SW: recurrence rate
• Sach-SW: targeted intraoperative radiotherapy (TARGIT)
• K10plus-PPN: 1793818398

Abstract

Purpose: Patients undergoing breast-conserving surgery were offered boost radiotherapy with targeted intraoperative radiotherapy (TARGIT) using the Intrabeam system to test the feasibility, safety, and efficacy of the new approach. Methods and Materials: We treated 302 cancers in 301 unselected patients. This was not a low-risk group. One-third of patients (98/301) were younger than 51 years of age. More than half of the tumors (172, 57%) were between 1 cm and 2 cm, and one-fifth (62, 21%) were > 2 cm; 29% (86) had a Grade 3 tumor and, in 29% (87), axillary lymph nodes contained metastasis. After primary surgery, 20 Gy was delivered intraoperatively to the surface of the tumor bed, followed by external-beam radiotherapy (EBRT), but excluding the usual boost. Results: The treatment was well tolerated. The follow-up ranged from 3 to 80 months (164 and 90 patients completed 2 and 3 years follow-up, respectively). Four patients (1.3%) had local recurrence. The Kaplan-Meier estimate of local recurrence is 2.6% (SE = 1.7) at 5 years. This compares favorably with the 4.3% recurrence rate in boosted patients from the EORTC boost study, in which only 8.1% patients were node-positive, as opposed to 29% in our series. Conclusion: Targeted intraoperative radiotherapy combined with EBRT results in a low local recurrence rate. This could be attributed to both accurate targeting and timeliness of the treatment. These data support the need for a randomized trial to test whether the TARGIT boost is superior to conventional external boost, especially in high-risk women. (c) 2006 Elsevier Inc.